Pharmaceutical

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen...

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on...

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

WEXFORD, Pa., Feb. 6, 2025 /PRNewswire/ -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated...

Analytical Standards Market to Grow by USD 657.8 Million (2024-2028) with Rapid Growth in the Life Science Industry Boosting the Market, Report on AI Impact on Market Trends – Technavio

error: Content is protected !!